Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15545513 | 0.83 | POLB (0.40) | POLBTDP1L3MBTL1CCR4EDNRA | |
| SCHEMBL17467165 | 0.81 | POLB (0.35) | POLBTDP1L3MBTL1CCR4EDNRA | |
| SCHEMBL17467171 | 0.78 | L3MBTL1 (0.36) | L3MBTL1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL17467163 | 0.77 | PAX8 (0.38) | POLBTDP1EDNRA | |
| SCHEMBL2006064 | 0.76 | SLC13A5 (0.41) | POLBTDP1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL5655847 | 0.73 | PTGDR2 (0.38) | POLBTDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL69183 | 0.71 | CLK1 (0.36) | POLBTDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL23878604 | 0.71 | LMNA (0.31) | KMT2A | |
| SCHEMBL21468504 | 0.71 | MEP1B (0.33) | MEN1KMT2A | |
| SCHEMBL18538068 | 0.71 | POLB (0.33) | POLBTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249160-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |